17 / 30
Page 89
conferenceseries
.com
Volume 7
Pharmaceutical Regulatory Affairs: Open Access
ISSN: 2167-7689
Pharma Europe 2018
May 07-09, 2018
May 07-09, 2018 | Frankfurt, Germany
15
th
Annual European Pharma Congress
Structure-based design for binding peptides in anti-cancer therapy
John Yu
Institute of Stem Cell and Translational Cancer Research, Taiwan
T
he conventional anticancer therapeutics usually lack cancer specificity, leading to damage of normal tissues that patients
find hard to tolerate. Ideally, anticancer therapeutics carrying payloads of drugs equipped with cancer targeting peptides
can act like “guided missiles” with the capacity of targeted delivery towards many types of cancers. Peptides are amenable
for conjugation to nano drugs for functionalization, thereby improving drug delivery and cellular uptake in cancer-targeting
therapies. Peptide drugs are oftenmore difficult to design throughmolecular docking and
in silico
analysis than small molecules,
because peptide structures are more flexible, possess intricate molecular conformations, and undergo complex interactions.
In this report, the development and application of strategies for structure-based design of cancer-targeting peptides against
GRP78 are discussed. This presentation will also cover topics related to peptide pharmacokinetics and targeting delivery,
including molecular docking studies, features that provide advantages for
in vivo
use, and properties that influence the cancer-
targeting ability. Some advanced technologies and special peptides that can overcome the pharmacokinetic challenges have
also been included.
johnyu@cgmh.org.tw csctcr.john@cgmh.org.twPharmaceut Reg Affairs 2018, Volume 7
DOI: 10.4172/2167-7689-C1-031